Surround sound technology treating high blood pressure

21 January 2016

High blood pressure is to be treated with a new surround sound system which sends ultrasound waves to the kidneys. The technique being trialled at Southampton General Hospital, called renal denervation, uses novel technology known as the Surround Sound Hypertension Therapy System to provide an alternative treatment for patients who have been unable to control […]

Continue Reading

Moximed Announces CE Mark and First Commercial Use of Atlas Knee System

18 November 2015

Moximed Announces CE Mark and First Commercial Use of AtlasTM Knee System Shock absorber for the knee designed to treat patients with medial knee osteoarthritis (OA) November 18, 2015 07:00 AM Eastern Standard Time HAYWARD, Calif.–(BUSINESS WIRE)–Moximed®, Inc. announced the CE Mark of the Atlas Knee System, its next-generation knee joint unloader for pre-arthroplasty patients. Coinciding […]

Continue Reading

Moximed Named One of the “Fierce 15” Medical Devices 2015

14 October 2015

The scoop: Moximed is shooting to change the standard of care for patients with knee osteoarthritis (OA) with its KineSpring Knee Implant System. Normally, patients with OA try to get by with pain medication and knee braces before opting for joint-altering surgery. Moximed’s product targets patients with mild and moderate knee OA whose pain is […]

Continue Reading

Visterra’s Monoclonal Antibody Demonstrated Significant Antiviral Activity in Phase 2a

05 October 2015

Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study – Study Achieved its Primary Endpoint of Reduction in Viral Shedding; Treatment with VIS410 Resulted in a 92% Reduction of Virus vs. Placebo –Study Results Support Further Development of VIS410 in Hospitalized Patients  with Influenza A Cambridge, MA – October 5, 2015 Visterra, Inc., a clinical-stage biotechnology company […]

Continue Reading

Vertex Venture Holdings gets funds to go global

Armed with a war chest of US$600 million (S$857 million), Singapore’s largest and oldest venture capital firm is going global. The infusion of cash will allow Vertex Venture Holdings to invest in start-ups in the hot seats of innovation and technological disruption – United States, Israel and China – after having been mainly focused on […]

Continue Reading

Medtronic to Acquire Twelve, Inc., Developer of Transcatheter Mitral Valve Replacement Device

25 August 2015

DUBLIN – August 25, 2015 – In support of the company’s therapy innovation strategy, Medtronic plc (NYSE: MDT) today announced that it has signed a definitive agreement to acquire Twelve, Inc. (“Twelve”), a privately-held medical device company based in Redwood City, Calif., focused on the development of a transcatheter mitral valve replacement(TMVR) device. Twelve is the twelfth […]

Continue Reading

Moximed Closes $33MM Financing Round

07 May 2015

Funding to Support Moximed’s Efforts to Obtain FDA Approval of KineSpring System HAYWARD, Calif.–(BUSINESS WIRE)–Moximed®, Inc., developer of the KineSpring® System, a joint unloading knee implant for pre-arthroplasty patients who hope to lead an active lifestyle, announced a round of financing of approximately $33MM that includes new investor Vertex Venture Holdings Ltd. (Vertex) and returning […]

Continue Reading

Visterra Closes $30 Million Series B Financing – Co-led by New Investors, Merck Research Labs Venture Fund, Vertex Venture Holdings and Temasek

02 October 2014

Cambridge, MA – October 2, 2014 Visterra, Inc., a biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics, today announced that it has completed a $30 million Series B financing round. The proceeds will be used to advance the development of multiple product candidates from the company’s […]

Continue Reading

Holaira Named FierceMedicalDevices’ 2014 Fierce 15

01 October 2014

The scoop: Drug options for chronic obstructive pulmonary disease (COPD) are only modestly effective. Holaira is betting that its lung denervation device can improve COPD treatment, either as a replacement for drugs or in addition to them. COPD is characterized by persistent airflow limitation caused by progressive narrowing of the airways. This leads to shortness […]

Continue Reading

Holaira Closes $42 Million Round – Investment led by Vertex Venture Holdings to Support Randomized Clinical Trial

03 April 2014

Minneapolis, MN, April 03, 2014 – Holaira, Inc., a developer of medical devices to treat obstructive lung diseases, today announced the completion of its Series D private equity financing, totaling $42 million led by Vertex Venture Holdings Ltd. Other participants in this financing round include Windham Venture Partners, two strategic investors, and all of Holaira’s […]

Continue Reading